

## UNITED STATES PATENT AND TRADEMARK OFFICE



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/833,838	04/10/1997	BRUCE D. GAYNOR	96700/451	3053
759	90 04/28/2003			
AMSTER ROTHSTEIN & EBENSTEIN			EXAMINER	
90 PARK AVENUE NEW YORK, NY 10016			EWOLDT, GERALD R	
			ART UNIT	PAPER NUMBER
			1644	70
			DATE MAILED: 04/28/2003	G G

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Advisory Action**

Application No. 08/833,838

Applicant(s)

Gaynor et al.

Examiner

G.R. Ewoldt

Art Unit 1644



	The MAILING DATE of this communication appears on the cover sheet with the correspondence address
There eject allow	REPLY FILED <u>Apr 9, 2003</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Store, further action by the applicant is required to avoid the abandonment of this application. A proper reply to a final tion under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for ance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination in compliance with 37 CFR 1.114.
	THE PERIOD FOR REPLY [check only a) or b)]
a)	The period for reply expires months from the mailing date of the final rejection.
b)	The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
ex ap se	ctensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate ctension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The propriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally it in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the ailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1.□	A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. 🗆	The proposed amendment(s) will not be entered because:
(a)	they raise new issues that would require further consideration and/or search (see NOTE below);
(b)	they raise the issue of new matter (see NOTE below);
(c)	they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d)	they present additional claims without canceling a corresponding number of finally rejected claims.
	NOTE:
3. 🗆	Applicant's reply has overcome the following rejection(s):
4. 🗆	Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. 🔀	The a) $\square$ affidavit, b) $\square$ exhibit, or c) $\boxtimes$ request for reconsideration has been considered but does NOT place the application in condition for allowance because:  See attachment
3.□	The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. 💢	For purposes of Appeal, the proposed amendment(s) a) $\square$ will not be entered or b) $\boxtimes$ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
	The status of the claim(s) is (or will be) as follows:
	Claim(s) allowed: none
	Claim(s) objected to: none
	Claim(s) rejected: <u>54-58 and 71-74</u>
	Claim(s) withdrawn from consideration:
3. 🗆	The proposed drawing correction filed on is a) $\square$ approved or b) $\square$ disapproved by the Examiner.
9. □	Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s)
ე.□	Other:

Serial No. 08/833,838 Art Unit 1644

## DETAILED ACTION

- As set forth in the rejection, mailed 6/28/02, the remaining issue is how the peptides of the instant claims could treat established glomerulonephritis. The specification discloses only a highly artificial model in which the treatment is administered at the same time disease is induced. That is, the peptide is administered simultaneously with the disease-inducing antibody. It is disclosed that at a single time point, just 15 hours after the treatment, deposition of the antibody in the glomeruli of the kidney is inhibited. This single disclosure cannot be considered to be enabling for a method of treating glomerulonephritis. There is no consideration or discussion regarding how the peptide treatment might actually clear antibodies already present and concentrated in the kidney (as would be seen in the actual disease). Further, even the specification discloses (at page 20) that a therapeutic strategy is merely "suggested". Clearly then, the method of the instant claims could not have been considered to be enabled in 1995, the priority date claimed by Applicants.
- 2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. The examiner can normally be reached Monday through Thursday and alternate Fridays from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

G.R. Ewoldt, Ph.D. Primary Examiner Technology Center 1600 April 25, 2003